92 related articles for article (PubMed ID: 6360031)
1. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease.
Jotkowitz S
Ann Neurol; 1983 Dec; 14(6):690-1. PubMed ID: 6360031
[TBL] [Abstract][Full Text] [Related]
2. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
Wettstein A
Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
[TBL] [Abstract][Full Text] [Related]
3. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
4. Memory enhancement with oral physostigmine in Alzheimer's disease.
N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
[No Abstract] [Full Text] [Related]
5. Oral physostigmine and lecithin improve memory in Alzheimer disease.
Thal LJ; Fuld PA; Masur DM; Sharpless NS
Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
[TBL] [Abstract][Full Text] [Related]
6. Cortisol responses to cholinergic drugs in Alzheimer's disease.
Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J
Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749
[TBL] [Abstract][Full Text] [Related]
7. Oral physostigmine in Alzheimer's disease.
Davis KL; Mohs RC; Davis BM; Horvath TB; Greenwald BS; Rosen WG; Levy MI; Johns CA
Psychopharmacol Bull; 1983; 19(3):451-3. PubMed ID: 6635123
[No Abstract] [Full Text] [Related]
8. Oral physostigmine treatment of patients with Alzheimer's disease.
Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
[TBL] [Abstract][Full Text] [Related]
9. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
Canal N; Imbimbo BP
Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
[TBL] [Abstract][Full Text] [Related]
10. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.
Peskind ER; Wingerson D; Pascualy M; Thal L; Veith RC; Dorsa DM; Bodenheimer S; Raskind MA
Biol Psychiatry; 1995 Oct; 38(8):532-8. PubMed ID: 8562665
[TBL] [Abstract][Full Text] [Related]
11. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
[TBL] [Abstract][Full Text] [Related]
13. Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease.
Levin HS; Peters BH
Ann Neurol; 1984 Feb; 15(2):210. PubMed ID: 6703661
[No Abstract] [Full Text] [Related]
14. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
15. Long-term outpatient treatment of senile dementia with oral physostigmine.
Beller SA; Overall JE; Rhoades HM; Swann AC
J Clin Psychiatry; 1988 Oct; 49(10):400-4. PubMed ID: 3049561
[TBL] [Abstract][Full Text] [Related]
16. Long-term administration of oral physostigmine in Alzheimer's disease.
Stern Y; Sano M; Mayeux R
Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
[TBL] [Abstract][Full Text] [Related]
17. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
[TBL] [Abstract][Full Text] [Related]
18. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.
Davidson M; Bierer LM; Kaminsky R; Ryan TM; Davis KL
Alzheimer Dis Assoc Disord; 1989; 3(4):224-7. PubMed ID: 2688700
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
